Hims & Hers Health Insider Trading Activity

Recent Insider Trading at Hims & Hers Health

In a recent transaction on December 24th, Michael Chi, an insider at Hims & Hers Health, Inc. (NYSE:HIMS), sold 17,303 shares of his company stock. The shares were sold at an average price of $27.97, accumulating a total of approximately $483,964.91. Following this sale, Chi now holds 193,601 shares valued at about $5,415,019.97, reflecting a decrease in his ownership by 8.20%.

Other Recent Trades by Michael Chi

• On December 19th, Chi sold 7,500 shares at $26.00, totaling $195,000.00.
• On December 10th, 7,259 shares were sold at $32.25, amounting to $234,102.75.
• On December 2nd, he sold 2,054 shares for $68,932.24.
• On October 25th, Chi sold 17,304 shares at $22.00, garnering a total of $380,688.00.
• On October 21st, he sold 7,500 shares at $22.20 for $166,500.00.

Recent Trading Performance

On December 27th, the stock traded down by 6.8%, reaching $26.56, with 8,844,547 shares exchanged during trading hours, compared to an average volume of 10,054,175 shares. Hims & Hers Health has a market capital of $5.80 billion, and its stock value has fluctuated between a low of $8.09 and a high of $35.02 in the last 52 weeks.

Earnings Report Insights

Hims & Hers Health reported quarterly earnings on November 4th, revealing earnings per share of $0.32, surpassing analyst expectations of $0.06. The company also generated $401.56 million in revenue, exceeding the $382.20 million forecast. This growth marks a 77.1% increase compared to the same quarter last year.

Institutional Investments

A notable increase in institutional holdings for Hims & Hers Health was also reported. Renaissance Technologies LLC increased its stake by 113.1%, now owning 6,039,408 shares valued at $121.936 million. Other firms like State Street Corp and Wellington Management Group have also enhanced their positions.

Analyst Ratings Overview

Recent ratings from analysts have been varied. Morgan Stanley initiated coverage with an “overweight” rating and a target price of $42.00, while Bank of America downgraded shares from a “buy” to an “underperform” rating, reducing the price target to $18.00. Overall, the consensus rating of Hims & Hers Health remains a “Hold” with target prices averaging around $22.80.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform connecting consumers to licensed healthcare professionals. Providing a range of health and wellness products, the company serves customers in the US and internationally.